Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension

NCT04954742 is registered in ClinicalTrials.gov with Heidelberg University as lead sponsor.

NCT NCT04954742
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04954742 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Prospective, Single Centre Study of the Effects of Riociguat on RIght VEntricular Size and Function in Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension
Lead sponsor
Heidelberg University
Phase
Phase 4
Overall status
Terminated
Start date
April 13, 2022
Completion date
August 13, 2025
Enrollment
30 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chronic thromboembolic pulmonary hypertension, primary pulmonary arterial hypertension